Torsten Wöhr, Head of Oligonucleotides, Bachem AG in Switzerland
Click HERE to download the PDF
BACHEM IS NOW EXPANDING INTO OLIGONUCLEOTIDES
The global market for oligonucleotide therapeutics is expanding rapidly. What is Bachem’s strategy in entering this competitive environment?
I think it is important for our customers to understand that the decision of the Bachem leadership to enter the field of oligonucleotide manufacturing was well-prepared and ultimately taken in line with the company’s long-term growth plan.
We are operative since 2019 and are gradually expanding our expert resource pool, capabilities and capacity for oligonucleotides.
We have been lucky to forge strong partnerships on the customer as well as on the supplier side and have been able to hire great oligonucleotide chemists to accelerate our organizational learning.
Despite having set ambitious goals we go step by step. Having said that, more and more w ...